Koichi Ito

Koichi Ito, PhD, is a Senior Director at Prelude Therapeutics, where he leads Biology Drug Discovery and Translational Research. Since joining Prelude in 2018, he has played a key role in advancing innovative therapeutic approaches, including targeted protein degraders (TPDs) and degrader antibody conjugates (DACs). Koichi completed his postdoctoral training at Columbia University and the Icahn School of Medicine at Mount Sinai in New York from 2012 to 2018. His postdoctoral research during this time focused on identifying novel therapies for patients with melanoma and triple-negative breast cancer (TNBC), supported by funding from Pfizer Inc. and Susan G. Komen Breast Cancer Foundation. He obtained his PhD in Cancer Biology and Immunology from Griffith University in Australia in 2012.